Alaunos Therapeutics annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2020
2021
2022
2023
2024
2025
Alaunos Therapeutics Revenue Growth & History (TCRT)
Alaunos Therapeutics reported $5,000 in revenue for fiscal 2025, a decrease of 50.00% from the previous fiscal year.
View full Alaunos Therapeutics company overviewAlaunos Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $5,000 | −$5,000 | −50.00% |
| 2024 | 2024-12-31 | $10,000 | $5,000 | +100.00% |
| 2023 | 2023-12-31 | $5,000 | −$2.9M | −99.83% |
| 2022 | 2022-12-31 | $2.9M | $2.5M | +634.17% |
| 2021 | 2021-12-31 | $398,000 | $398,000 | — |
| 2020 | 2020-12-31 | $0 | — | — |
| 2018 | 2018-12-31 | $146,000 | −$6.2M | −97.71% |
| 2017 | 2017-12-31 | $6.4M | −$472,000 | −6.88% |
| 2016 | 2016-12-31 | $6.9M | $2.5M | +58.38% |
| 2015 | 2015-12-31 | $4.3M | $3.0M | +215.51% |
| 2014 | 2014-12-31 | $1.4M | $573,000 | +71.63% |
| 2013 | 2013-12-31 | $800,000 | $0 | 0.00% |
| 2012 | 2012-12-31 | $800,000 | $133,000 | +19.94% |
| 2011 | 2011-12-31 | $667,000 | — | — |
Alaunos Therapeutics quarterly revenue
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.20
Q2.20
Q3.20
Q4.20
Q3.21
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | −$2,000 | −100.00% |
| Q4 2025 | 2025-12-31 | $3,000 | −$2,000 | −40.00% |
| Q3 2025 | 2025-09-30 | $0 | $0 | — |
| Q2 2025 | 2025-06-30 | $0 | −$4,000 | −100.00% |
| Q1 2025 | 2025-03-31 | $2,000 | $1,000 | +100.00% |
| Q4 2024 | 2024-12-31 | $5,000 | $4,000 | +400.00% |
| Q3 2024 | 2024-09-30 | $0 | $0 | — |
| Q2 2024 | 2024-06-30 | $4,000 | $0 | 0.00% |
| Q1 2024 | 2024-03-31 | $1,000 | $1,000 | — |
| Q4 2023 | 2023-12-31 | $1,000 | — | — |
| Q3 2023 | 2023-09-30 | $0 | −$2.9M | −100.00% |
| Q2 2023 | 2023-06-30 | $4,000 | $4,000 | — |
| Q1 2023 | 2023-03-31 | $0 | — | — |
| Q3 2022 | 2022-09-30 | $2.9M | $2.5M | +631.41% |
| Q2 2022 | 2022-06-30 | $0 | — | — |
| Q3 2021 | 2021-09-30 | $398,000 | $398,000 | — |
| Q4 2020 | 2020-12-31 | $0 | — | — |
| Q3 2020 | 2020-09-30 | $0 | — | — |
| Q2 2020 | 2020-06-30 | $0 | — | — |
| Q1 2020 | 2020-03-31 | $0 | — | — |
| Q4 2018 | 2018-12-31 | $0 | −$1.6M | −100.00% |
| Q3 2018 | 2018-09-30 | $0 | −$1.6M | −100.00% |
| Q2 2018 | 2018-06-30 | $0 | −$1.6M | −100.00% |
| Q1 2018 | 2018-03-31 | $146,000 | −$1.5M | −90.86% |
| Q4 2017 | 2017-12-31 | $1.6M | $0 | 0.00% |
| Q3 2017 | 2017-09-30 | $1.6M | $0 | 0.00% |
| Q2 2017 | 2017-06-30 | $1.6M | −$100,000 | −5.89% |
| Q1 2017 | 2017-03-31 | $1.6M | −$372,000 | −18.89% |
| Q4 2016 | 2016-12-31 | $1.6M | −$322,000 | −16.78% |
| Q3 2016 | 2016-09-30 | $1.6M | −$271,000 | −14.50% |
| Q2 2016 | 2016-06-30 | $1.7M | $1.4M | +523.90% |
| Q1 2016 | 2016-03-31 | $2.0M | $1.7M | +623.90% |
| Q4 2015 | 2015-12-31 | $1.9M | $1.6M | +464.41% |
| Q3 2015 | 2015-09-30 | $1.9M | $1.2M | +195.26% |
| Q2 2015 | 2015-06-30 | $272,000 | $72,000 | +36.00% |
| Q1 2015 | 2015-03-31 | $272,000 | $72,000 | +36.00% |
| Q4 2014 | 2014-12-31 | $340,000 | $140,000 | +70.00% |
| Q3 2014 | 2014-09-30 | $633,000 | $433,000 | +216.50% |
| Q2 2014 | 2014-06-30 | $200,000 | $0 | 0.00% |
| Q1 2014 | 2014-03-31 | $200,000 | $0 | 0.00% |
| Q4 2013 | 2013-12-31 | $200,000 | $0 | 0.00% |
| Q3 2013 | 2013-09-30 | $200,000 | $0 | 0.00% |
| Q2 2013 | 2013-06-30 | $200,000 | $0 | 0.00% |
| Q1 2013 | 2013-03-31 | $200,000 | $0 | 0.00% |
| Q4 2012 | 2012-12-31 | $200,000 | $0 | 0.00% |
| Q3 2012 | 2012-09-30 | $200,000 | $0 | 0.00% |
| Q2 2012 | 2012-06-30 | $200,000 | $0 | 0.00% |
| Q1 2012 | 2012-03-31 | $200,000 | $133,000 | +198.51% |
| Q4 2011 | 2011-12-31 | $200,000 | — | — |
| Q3 2011 | 2011-09-30 | $200,000 | — | — |
| Q2 2011 | 2011-06-30 | $200,000 | — | — |
| Q1 2011 | 2011-03-31 | $67,000 | — | — |
Alaunos Therapeutics revenue growth trends
Alaunos Therapeutics's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Alaunos Therapeutics source filings ↗